X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (274) 274
immunotherapy (243) 243
humans (226) 226
animals (204) 204
immunology (171) 171
cancer (170) 170
oncology (147) 147
ctla-4 (132) 132
t cells (119) 119
ctla-4 blockade (118) 118
mice (118) 118
melanoma (105) 105
tumors (89) 89
lymphocytes (88) 88
lymphocytes t (88) 88
care and treatment (87) 87
ctla-4 antigen (87) 87
ctla-4 protein (84) 84
antigens (78) 78
pd-1 (76) 76
ipilimumab (75) 75
regulatory t-cells (75) 75
antibodies, monoclonal - therapeutic use (73) 73
t-lymphocytes - immunology (72) 72
neoplasms - immunology (70) 70
dendritic cells (69) 69
metastatic melanoma (69) 69
immune checkpoint (67) 67
female (66) 66
immunotherapy - methods (66) 66
article (64) 64
antitumor immunity (60) 60
colony-stimulating factor (60) 60
ctla-4 antigen - antagonists & inhibitors (57) 57
ctla-4 antigen - immunology (57) 57
immune response (57) 57
mice, inbred c57bl (57) 57
neoplasms - therapy (57) 57
in-vivo (54) 54
immune system (52) 52
expression (49) 49
abatacept (48) 48
cytotoxicity (48) 48
research (48) 48
t cell receptors (48) 48
analysis (47) 47
chemical and pharmacologic phenomena (47) 47
antibodies (43) 43
review (43) 43
t-cells (43) 43
male (42) 42
t-lymphocytes, regulatory - immunology (42) 42
health aspects (41) 41
lymphocyte activation (41) 41
transplantation (41) 41
cd8-positive t-lymphocytes - immunology (40) 40
antigens, cd - immunology (39) 39
programmed cell death 1 receptor - antagonists & inhibitors (39) 39
antigens, cd (38) 38
cytokines (38) 38
immunity (37) 37
medicine, research & experimental (37) 37
mice, inbred balb c (37) 37
pd-1 protein (37) 37
cell biology (36) 36
chemotherapy (36) 36
metastasis (36) 36
antigens, differentiation - immunology (35) 35
clinical trials (35) 35
monoclonal antibodies (35) 35
pd-1 blockade (35) 35
costimulation (34) 34
metastases (34) 34
surgery (34) 34
apoptosis (33) 33
therapy (33) 33
activation (32) 32
antibodies, monoclonal - pharmacology (32) 32
cd28 antigens - immunology (32) 32
cd8 antigen (32) 32
drug therapy (32) 32
multidisciplinary sciences (32) 32
survival (32) 32
antineoplastic agents - therapeutic use (31) 31
autoimmunity (31) 31
flow cytometry (31) 31
immunoconjugates (31) 31
vaccines (31) 31
combination immunotherapy (30) 30
combined modality therapy (29) 29
medical research (29) 29
programmed cell death 1 receptor - immunology (29) 29
radiotherapy (29) 29
cell line, tumor (28) 28
tumor microenvironment (28) 28
cancer therapies (27) 27
cd4-positive t-lymphocytes - immunology (27) 27
ctla-4 antigen - metabolism (27) 27
medicine (27) 27
monoclonal-antibody (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


OncoImmunology, ISSN 2162-4011, 07/2012, Volume 1, Issue 4, pp. 544 - 546
We report that cryoablation of primary tumors synergizes with anti-CTLA-4 treatment to mediate rejection of secondary tumors in the TRAMP mouse model of... 
Ipilumimab | prostate cancer | CTLA-4 | SPAS-1 | cryoablation | Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Cryoablation | Prostate cancer | IMMUNITY | MELANOMA | ONCOLOGY | COMBINATION IMMUNOTHERAPY | IMMUNOLOGY | CANCER
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/1998, Volume 95, Issue 17, pp. 10067 - 10071
Journal Article
Oncoimmunology, ISSN 2162-4011, 07/2012, Volume 1, Issue 4, pp. 544 - 546
We report that cryoablation of primary tumors synergizes with anti-CTLA-4 treatment to mediate rejection of secondary tumors in the TRAMP mouse model of... 
Ipilumimab | prostate cancer | CTLA-4 | SPAS-1 | Author's View | cryoablation
Journal Article
by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Amy and Smith, Sean and Smith, Myles and Smith, Elaine and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Swanton, Charles and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Benjamin and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Turajlic, Samra and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Matthews, Sue and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and Thakrar, Ricky and Forster, Martin and Ahmad, Tanya and Lee, Siow Ming and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 5/2016, Volume 65, Issue 5, pp. 537 - 549
The dramatic clinical benefit of immune checkpoint blockade for a fraction of cancer patients suggests the potential for further clinical benefit in a broader... 
Active immunotherapy | Immunology | Poxvirus | Medicine & Public Health | Immune checkpoint blockade | Anti-CTLA-4 | Oncology | Cancer Research | Modified Vaccinia Ankara (MVA) | Cancer | ANTITUMOR RESPONSES | VACCINE | SELF-ANTIGEN | INDUCTION | IMMUNOLOGY | COMBINATION | EFFECTOR | ONCOLOGY | RANDOMIZED PHASE-II | GM-CSF | RESISTANT PROSTATE-CANCER | IPILIMUMAB | Immunotherapy - methods | Cancer Vaccines - pharmacology | Humans | Vaccinia virus - genetics | Vaccinia virus - immunology | T-Lymphocytes, Regulatory - immunology | Neoplasms, Experimental - pathology | T-Lymphocytes, Cytotoxic - drug effects | Flow Cytometry | Lung Neoplasms - secondary | Neoplasms, Experimental - immunology | Antibodies - immunology | CD8-Positive T-Lymphocytes - metabolism | Female | Cytokines - immunology | T-Lymphocytes, Cytotoxic - immunology | Tumor Microenvironment - drug effects | Cytokines - metabolism | Neoplasms, Experimental - therapy | CTLA-4 Antigen - immunology | Antibodies - pharmacology | Drug Synergism | Tumor Microenvironment - immunology | Cancer Vaccines - immunology | Lung Neoplasms - immunology | T-Lymphocytes, Regulatory - drug effects | Animals | Lung Neoplasms - prevention & control | CD8-Positive T-Lymphocytes - drug effects | Survival Analysis | Cell Line, Tumor | Mice, Inbred BALB C | CD8-Positive T-Lymphocytes - immunology | CTLA-4 Antigen - antagonists & inhibitors | Antiviral agents | Analysis | Immunotherapy | Metastasis | Drug therapy | T cells | Original
Journal Article
EBioMedicine, ISSN 2352-3964, 03/2019, Volume 41, pp. 146 - 155
Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including... 
Anti-cancer vaccine | Innate immunity | RIG-I | Immune checkpoint inhibitors | Dendritic cells | Immuno-oncology | MEDICINE, RESEARCH & EXPERIMENTAL | RECOGNITION | PD-1 BLOCKADE | TUMORS | INTERFERON | IMMUNOTHERAPY | REJECTION | INFLAMMASOME | CTLA-4 | T-CELLS
Journal Article
Cancer research, ISSN 0008-5472, 10/2009, Volume 69, Issue 19, pp. 7747 - 7755
The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations and aberrations in gene expression. As few of these changes... 
CTLA-4 | Flt3-ligand | GM-CSF | Immunotherapy | Melanoma
Journal Article
14.